Ionis Pharmaceuticals (IONS) FDA announcement summary

Introduction and purpose

• ZANVASTRO (zilganersen) received FDA approval as the first and only disease-modifying treatment for Alexander disease (AxD) in both pediatric and adult patients.

• Alexander disease is an ultra-rare, progressive, and often fatal neurological disorder with significant unmet medical need and limited prior treatment options.

Details of approval or decision

• FDA approved ZANVASTRO for children and adults with Alexander disease, with a broad label and approval granted nearly three weeks ahead of schedule.

• Approval was based on pivotal study results showing statistically significant and clinically meaningful stabilization of motor function, with a favorable safety and tolerability profile.

• A Rare Pediatric Disease Priority Review Voucher was awarded alongside approval, offering the opportunity to accelerate future FDA reviews.

• ZANVASTRO will be available in the U.S. within weeks of approval.

• Regulatory submissions in Europe and Japan are planned for 2027.

Impact on industry and stakeholders

• ZANVASTRO marks the first independent commercial neurology launch, expanding commercial capabilities and supporting future launches in rare neurological diseases.

• Provides a new treatment paradigm for AxD, shifting focus from symptom management to disease modification.

• Strong partnership with the Alexander disease patient community and strategies to improve diagnosis and access.

• Patient and caregiver support services will be offered, including education and insurance assistance.

• Commercial expansion is planned internationally, with filings in the EU and Japan expected next year and ongoing collaboration with Recordati for regulatory submissions outside the U.S. in 2027.